Integrase

Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection

25 views | Jun 27 2023

Cabotegravir (Apretude) is an extended-release injectable HIV-1 antiretroviral medication used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in HIV-negative individuals at high risk. [Read the Full Post]

Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis

50 views | Jun 26 2023

The study found that long-acting injectable cabotegravir (CAB-LA) was more effective than daily oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) in preventing HIV infection among at-risk cisgender men who have sex with men (MSM) and transgender women who have sex with men. [Read the Full Post]

Acute Care Management of the HIV-Infected Patient: A Report from the HIV Practice and Research Network of the American College of Clinical Pharmacy

16 views | Mar 28 2023

This report provides guidance for clinicians managing HIV-infected patients and antiretroviral therapy in the inpatient setting, highlighting the need for a thorough medication history, consideration of drug-drug interactions and organ dysfunction, and timely follow-up to prevent medication errors and readmissions. [Read the Full Post]

Iatrogenic Cushing's Syndrome: The Result of Cobicistat and Glucocorticoid Interaction in an HIV Patient After Bariatric Surgery

31 views | Mar 27 2023

The case report describes a patient with HIV-hepatitis C virus co-infection who developed iatrogenic Cushing's syndrome due to an interaction between cobicistat-boosted darunavir and inhaled corticosteroids after undergoing sleeve gastrectomy for morbid obesity. [Read the Full Post]

In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing

29 views | Mar 13 2023

The study aimed to identify potential drugs against Omicron by testing previously repurposed anti-COVID-19 drugs, and raltegravir and hesperidin were found to have high binding affinities and stabilities to Omicron and may be potential drugs, but further clinical studies are needed to confirm their efficacy and safety. [Read the Full Post]

Real-World Characterization of the Portuguese Population Living with HIV who Initiated Raltegravir Based-Regimens: The REALITY Study

44 views | Aug 02 2022

Rosário Serrão et al. showed that raltegravir-based regimens seemed like a valid therapeutic option in heterogeneous populations of HIV-infected patients, in patients with previous ART experience and as part of first-line therapeutic options alongside with the latest generation of drugs from its class. [Read the Full Post]

Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach

264 views | Sep 08 2021

Zahra Molavi et al. recommended further experimental evaluations in vitro and in vivo on FDA-approved drugs to assess their potential antiviral effect on SARS-CoV-2. [Read the Full Post]

Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding

274 views | Aug 24 2020

Rumbidzai Chitongo et al. suggested the G140S mutant had the strongest effect on the HIV-1C IN protein structure and Dolutegravir binding. [Read the Full Post]

Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients

885 views | Nov 06 2019

Brehm TT et al. showed that side effects were only rarely observed and generally mild in all subgroups. In light of a slightly higher incidence of vertigo and sleep disturbances in patients switched to DTG, awareness of the potential onset of psychiatric symptoms is warranted during follow-up in those patients. [Read the Full Post]

Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1

480 views | Jun 20 2019

Evering TH et al. indicated it has demonstrated a favorable side-effect profile in treatment-naive and -experienced patients and a subset of heavy treatment-experienced patients have been able a achieve virologic suppression with raltegravir as part of combination therapy despite limited treatment options. [Read the Full Post]